Viral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in Ghana

详细信息    查看全文

• 作者：Omobolawa Kukoyi ; Lorna Renner ; Jonathan Powell ; Oliver Barry…
• 关键词：Pediatric HIV ; Cumulative viral load ; viral copy years ; Morbidity ; Resource ; limited setting
• 刊名：BMC Infectious Diseases
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：16
• 期：1
• 全文大小：1,434 KB
• 参考文献：1.UNAIDS. Global Report. UNAIDS report on the global AIDS epidemic 2013 [http://​www.​unaids.​org/​sites/​default/​files/​en/​media/​unaids/​contentassets/​documents/​epidemiology/​2013/​gr2013/​UNAIDS_​Global_​Report_​2013_​en.​pdf ]. Accessed 1 Oct 2015.
  2.Optimizing treatment options and improving access to priority products for children living with HIV Brief [http://​www.​who.​int/​hiv/​pub/​toolkits/​paediatric_​art_​optimisation
  ief/​en/​ ]. Accessed 1 Oct 2015.
  3.World Health Organization WH. WHO Early Release Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV September 2015. In. Geneva; 2015. [http://​www.​who.​int/​hiv/​pub/​guidelines/​en/​ ]. Accessed 1 Oct 2015.
  4.Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–54.CrossRef PubMed
  5.Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296(7):827–43.CrossRef PubMed
  6.World Health Organization Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for public health approach. [http://​whqlibdoc.​who.​int/​publications/​2010/​9789241599818_​eng.​pdf .]. Accessed 20 August 2015.
  7.Taiwo BO, Murphy RL. Clinical applications and availability of CD4+ T cell count testing in sub-Saharan Africa. Cytometry B Clin Cytom. 2008;74 Suppl 1:S11–18.CrossRef PubMed
  8.Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298(16):1888–99.CrossRef PubMed
  9.Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23(9):1127–34.PubMedCentral CrossRef PubMed
  10.Emmett SD, Cunningham CK, Mmbaga BT, Kinabo GD, Schimana W, Swai ME, et al. Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. J Acquir Immune Defic Syndr. 2010;54(4):368–75.PubMedCentral CrossRef PubMed
  11.Ruel TD, Kamya MR, Li P, Pasutti W, Charlebois ED, Liegler T, et al. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr. 2011;56(1):44–50.PubMedCentral CrossRef PubMed
  12.Davies MA, Ford N, Rabie H, Fatti G, Stinson K, Giddy J, et al. Reducing CD4 Monitoring in Children on Antiretroviral Therapy with Virologic Suppression. Pediatr Infect Dis J. 2015.
  13.Barry O, Powell J, Renner L, Bonney EY, Prin M, Ampofo W, et al. Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana. BMC Infect Dis. 2013;13:476.PubMedCentral CrossRef PubMed
  14.Germanaud D, Derache A, Traore M, Madec Y, Toure S, Dicko F, et al. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother. 2010;65(1):118–24.CrossRef PubMed
  15.Adje-Toure C, Hanson DL, Talla-Nzussouo N, Borget MY, Kouadio LY, Tossou O, et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d'Ivoire. AIDS Res Hum Retrovir. 2008;24(7):911–7.CrossRef PubMed
  16.Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13.PubMedCentral CrossRef PubMed
  17.Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V. Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J. 2009;28(9):826–30.CrossRef PubMed
  18.Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis. 2007;44(1):128–34.CrossRef PubMed
  19.Sawe FK, McIntyre JA. Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes. Clin Infect Dis. 2009;49(3):463–5.CrossRef PubMed
  20.Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375(9709):123–31.CrossRef PubMed
  21.Harrigan R. Measuring viral load in the clinical setting. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S34–40.PubMed
  22.Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet. 2008;371(9622):1443–51.CrossRef PubMed
  23.Renner L, Prin M, Li FY, Goka B, Northrup V, Paintsil E. Time to and Predictors of CD4+ T-Lymphocytes Recovery in HIV-Infected Children Initiating Highly Active Antiretroviral Therapy in Ghana. AIDS Res Treat. 2011;2011:896040.PubMedCentral PubMed
  24.Cole SR, Napravnik S, Mugavero MJ, Lau B, Eron Jr JJ, Saag MS. Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol. 2010;171(2):198–205.PubMedCentral CrossRef PubMed
  25.Consolidated Guidelines on the use of Antiretroviral Drugs for Treating and Preventing HIV Infection [http://​www.​who.​int/​hiv/​pub/​guidelines/​arv2013/​en/​ ]. Accessed 20 Aug 2015.
  26.Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, Klein M, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205(8):1230–8.PubMedCentral CrossRef PubMed
  27.Zoufaly A, Kiepe JG, Hertling S, Hufner A, Degen O, Feldt T, et al. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals. HIV Med. 2014;15(8):449–57.CrossRef PubMed
  28.Lambert-Niclot S, Flandre P, Valantin MA, Peytavin G, Duvivier C, Haim-Boukobza S, et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis. 2011;204(8):1211–6.CrossRef PubMed
  29.Boufassa F, Saez-Cirion A, Lechenadec J, Zucman D, Avettand-Fenoel V, Venet A, et al. CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One. 2011;6(4), e18726.PubMedCentral CrossRef PubMed
  30.Cohen Stuart JW, Wensing AM, Kovacs C, Righart M, de Jong D, Kaye S, et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001;28(2):105–13.CrossRef PubMed
  31.Macias J, Palomares JC, Mira JA, Torres MJ, Garcia-Garcia JA, Rodriquez JM, et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect. 2005;51(3):195–200.CrossRef PubMed
  32.Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010;53(1):86–94.PubMedCentral CrossRef PubMed
  33.O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334(7):426–31.CrossRef PubMed
  34.Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272(5265):1167–70.CrossRef PubMed
  35.Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice. Nat Med. 1996;2(6):625–9.CrossRef PubMed
  36.Lynen L, Van Griensven J, Elliott J. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings. Curr Opin HIV AIDS. 2010;5(1):1–5.CrossRef PubMed
  37.Coetzer M, Westley B, Delong A, Tray C, Sophearin D, Nerrienet E, et al. Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-line antiretroviral therapy by WHO 2010 guidelines. AIDS Res Hum Retrovir. 2013;29(7):985–92.PubMedCentral CrossRef PubMed
  38.Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankale JL, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011;53(12):1283–90.PubMedCentral CrossRef PubMed
  39.Lee KJ, Shingadia D, Pillay D, Walker AS, Riordan A, Menson E, et al. Collaborative HIVPSSC: Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean? Antivir Ther. 2007;12(6):949–56.PubMed
  40.Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA. 2001;286(2):196–207.CrossRef PubMed
  41.Thorvaldsson OPE, Northrup V, Andiman W. Cumulative viremai-copy years predicts morbidity and mortality in perinatally HIV-infected children. In: IDWeek. San Francisco: Infectious Diseases Society of America; 2013.
  42.Rossouw TM, Feucht UD, Melikian G, van Dyk G, Thomas W, du Plessis NM, et al. Factors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South Africa. PLoS One. 2015;10(7), e0133452.PubMedCentral CrossRef PubMed
  43.Mugavero MJ, Napravnik S, Cole SR, Eron JJ, Lau B, Crane HM, et al. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis. 2011;53(9):927–35.PubMedCentral CrossRef PubMed
  44.Kowalkowski MA, Day RS, Du XL, Chan W, Chiao EY. Cumulative HIV viremia and non-AIDS-defining malignancies among a sample of HIV-infected male veterans. J Acquir Immune Defic Syndr. 2014;67(2):204–11.PubMedCentral CrossRef PubMed
  45.Zoufaly A, Stellbrink HJ, Heiden MA, Kollan C, Hoffmann C, van Lunzen J, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis. 2009;200(1):79–87.CrossRef PubMed
  46.Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007;12(1):83–8.PubMed
  47.Belec L, Bonn JP. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less. Futur Microbiol. 2011;6(11):1251–60.CrossRef
  48.Roberts T, Bygrave H, Fajardo E, Ford N. Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc. 2012;15(2):17324.PubMedCentral CrossRef PubMed
  
• 作者单位：Omobolawa Kukoyi (1)
  Lorna Renner (2)
  Jonathan Powell (3)
  Oliver Barry (4)
  Meghan Prin (5)
  Jonas Kusah (2)
  Xiangyu Cong (6)
  Elijah Paintsil (7)
  
  1. From Duke University School of Medicine, Durham, NC, USA
  2. University of Ghana School of Medicine and Dentistry, Accra, Ghana
  3. Weill Cornell Medical College, New York, NY, USA
  4. Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
  5. Columbia University, New York, NY, USA
  6. Yale Center for Analytical Sciences, Yale School of Medicine, New Haven, CT, USA
  7. Departments of Pediatrics, Pharmacology & Public Health, Yale University School of Medicine, 464 Congress Avenue, New Haven, CT, 06520, USA
  
• 刊物主题：Infectious Diseases; Parasitology; Medical Microbiology; Tropical Medicine; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2334

文摘

Background HIV-infected children in sub-Saharan Africa may be at a high risk of staying on a failing first-line regimen and developing drug-resistance HIV variants due to lack of routine viral load monitoring. We investigated whether cumulative viral load, measured as viremia copy-years (VCY) could predict morbidity in a setting where viral load is not routinely monitored.